Head-to-head · WeighScore
Belle Health vs Invigor Medical
The verdict
Invigor Medical takes it — 86.1/100 to 73.8/100.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. An established pharmacy operator with steady mid-market pricing and a broad catalog.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Belle Health | Invigor Medical |
|---|---|---|
| WeighScore | 73.8/100 | 86.1/100 |
| Grade | C | B |
| Site position | #75 | #10 |
| Semaglutide | From $109/mo (compounded; supply terms unverified) | $199/mo |
| Tirzepatide | From $179/mo (compounded; supply terms unverified) | $339/mo |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Site position #75 · C
FDAWarning letter issued to Belle Health LLC dba Belle in February 2026. See the FDA warning-letter database.
Strengths
- Weekly live group sessions with a named registered dietitian are included
- Provider review, nurse support, injection supplies and shipping are included
- Advertises the same price across dose levels
- Terms state telehealth availability in all 50 states
Where it loses points
- Starting prices do not establish the required supply length, upfront charge or renewal amount
- Compounded medications are not FDA-approved finished products
- Prescription products are nonrefundable after shipment; subscriptions may renew automatically
- FDA issued Belle Health LLC dba Belle a warning letter in February 2026; the letter is public in FDA's warning-letter database
Site position #10 · B
Strengths
- Mid-market pricing on both molecules
- Long-running operator
Where it loses points
- No explicit states list
- Compounded only
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.